# Response Summary

## Task
Reviewed the draft Pre-Submission (Q-Sub) package for the VascuClear 3000 catheter-based thrombectomy device and prepared a prioritized issue memorandum.

## Deliverable
**`output/presub-issue-memorandum.docx`** — validated .docx (ECMA-376 / OOXML integrity check passed).

## Documents reviewed
1. `presub-cover-letter.docx`
2. `device-description-predicate-comparison.docx`
3. `proposed-testing-plan.docx`
4. `clinical-study-synopsis.docx`
5. `draft-ifu-vasculear-3000.docx`
6. `thrombex-200-510k-summary.docx` (predicate K192847)
7. `internal-email-chain-reg-strategy.eml` (context: memorandum authored by Daniel J. Yoo, Senior Associate, per Kate Pressman's instruction; due by the May 19, 2025 internal deadline)

## Approach
The memorandum is written in the voice of Daniel J. Yoo (Senior Associate, Hargrove, Templeton & Bliss LLP), addressed to Kate Pressman, dated May 19, 2025, and marked privileged & confidential / attorney work product — consistent with the email chain that assigned the review. It directly answers the two open strategic questions Kate raised (combination-product status; IDE requirement) and surfaces 23 additional deficiencies found across the package.

## Issues identified (25 total, in 4 priority tiers)
- **Tier 1 — Critical (5):** combination-product classification (no FDA question included); IDE requirement (study mischaracterized as "post-clearance"); predicate lacks drug-delivery capability and any rotating impeller; biocompatibility contact-duration misclassification (72 h indwell vs. "limited <24 h"); impeller fatigue test definitionally flawed (500 revolutions = ~2.5 s).
- **Tier 2 — High (7):** software level of concern understated ("Minor" vs. predicate's "Moderate"); bench testing excludes the combined pharmacomechanical function; drug-delivery characterization uses saline only; EMC testing omitted; shelf-life/sterile-barrier testing omitted; indication inconsistent with combination-product-avoidance strategy; program timeline internally infeasible vs. the Dec 31, 2025 milestone.
- **Tier 3 — Medium (10):** misstated predicate indication in Appendix A; console dimension/weight inconsistency; impeller-material inconsistency; incomplete MRI labeling; missing console reprocessing validation; missing hydrophilic-coating integrity testing; unjustified clinical performance goal; incomplete study governance (no DSMB/CEC); tPA dosing lacks safety guardrails; premature pathway statement.
- **Tier 4 — Lower (3):** IFU allergy materials list incomplete; hemocompatibility gaps for rotating impeller/nitinol; 30-day follow-up may be insufficient for PTS.

Each issue includes where it appears, analysis, and a specific recommendation. The memo also provides a consolidated list of recommended additions/revisions to the FDA questions and cross-cutting next steps, and recommends adding both the combination-product and IDE questions to the Pre-Submission (consistent with Kate Pressman's position).

## Validation
`python skills/docx/scripts/validate.py output/presub-issue-memorandum.docx` → exit 0 (valid).